Dishman Pharma & Chem Peer Comparison

NSE: DISHMAN | BSE: 532526

₹301.20

₹7.95 (2.71%)

As on 29-May-2017IST

Market cap

₹4,859 Cr

Revenue (TTM)

₹1,672 Cr

P/E Ratio

30.1

P/B Ratio

Div. Yield

0.4 %

Edit

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	4,859	29,384	27,439	25,841	24,478
Revenue (₹ Cr)	1,672	3,564	1,462	9,205	1,936
Net Profit (₹ Cr)	162.05	414.00	387.35	-371.81	288.22
Net Margin (%)	9.50	11.23	26.01	-3.93	14.79
RoE (%)	4.97	8.38	25.18	-3.85	29.77
Price to Earnings	30.15	71.84	71.04	--	84.93
Price-To-Book	1.01	5.84	15.90	3.23	18.24

Income Statement (₹ Cr)

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	1,596.05	4,453.22	153.70	--	39.17
Total Income	1,622.59	4,519.32	156.57	--	39.64
Total Expenditure	1,185.73	3,958.98	135.51	--	29.32
EBITDA	410.32	494.24	18.19	--	9.85
Depreciation	109.06	141.91	0.80	--	4.71
EBIT	301.26	352.33	17.39	--	5.13
Interest	94.44	128.96	2.56	--	2.64
Other Income	26.54	66.10	2.87	--	0.47
Exceptional Items	--	--	--	--	--
Profit before Tax	233.36	289.47	17.70	--	2.96
Provision for Tax	62.36	37.88	5.04	--	2.05
Profit after Tax	171.00	251.59	12.66	--	0.92

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	1,451.55	3,775.12	27.42	--	48.41
Minority Interest	0.44	465.33	--	--	--
Non-Current Liabilities	576.84	1,893.49	15.21	--	12.24
Current Liabilities	951.70	1,841.85	48.60	--	31.04
Total Liabilities	2,980.53	8,073.64	92.39	--	91.69

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	1,878.74	4,023.94	24.90	--	56.39
Current Assets	1,101.79	3,951.85	66.17	--	35.29
Total Assets	2,980.53	8,073.64	92.39	--	91.69
Total Debt*	942.81	2,676.60	29.75	--	28.89
Net Current Assets	150.09	2,110.00	17.57	--	4.26
Contingent Liabilities	249.22	273.87	--	--	--

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	278.64	71.61	9.86	--	7.61
Cash Flow from Investing Activities	-152.89	-818.19	-14.23	--	-7.87
Cash from Financing Activities	-94.10	254.26	4.37	--	-0.26
Net Cash Inflow / Outflow	31.65	-492.32	-0.01	--	-0.51

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	14.40	6.87	35.54	--	7.44
ROE (%)	12.77	7.07	46.43	--	3.16
ROA (%)	5.91	3.25	13.87	--	1.04
EBIT Margin (%)	27.37	12.58	13.70	--	26.35
Net Margin (%)	10.54	5.57	8.08	--	2.31
Cash Profit Margin (%)	17.48	8.84	8.75	--	14.36

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	0.46	-0.63	0.00	--	-0.11
EBIT Growth (%)	9.32	-27.79	24.42	--	-10.14
Net Profit Growth (%)	42.79	-39.04	0.00	--	-65.67
EPS Growth (%)	42.82	-38.31	0.00	--	-65.67
Book Value Growth (%)	17.34	11.15	0.00	--	3.21

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	7.92	39.52	0.00	--	0.00
Price / Book Value	1.87	2.87	0.00	--	0.00
Dividend Yield (%)	0.60	0.00	--	--	--
EV/EBITDA	8.22	21.33	1.46	--	4.77
Market Cap (₹ Cr)	2,710.31	10,753.31	0.00	--	0.00

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.65	0.71	1.09	--	0.60
Short term debt to equity ratio	0.29	0.15	0.42	--	0.31
Current Ratio	1.16	2.15	1.36	--	1.14
Quick Ratio	0.65	1.55	0.96	--	1.07
Interest Coverage	3.47	3.24	7.92	--	2.12

	Dishman Pharma & Chem	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	9.54	24.96	23.62	--	48.35
Asset Turnover	0.55	0.58	1.68	--	0.45
Receivable days	42.08	75.93	86.20	--	166.45
Inventory Days	106.08	87.00	46.64	--	13.89
Payable days	129.38	134.61	113.37	--	247.85
Cash Conversion Cycle	18.78	28.32	19.47	--	-67.51

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.